EVENTS|NEWS|CONTACT|DONATE

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Read Our Newsletter

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Day

November 24, 2025

Research Scholar Investigates Novel Immune Target in Gastric Cancer

Over the past three years, Martina Molgora, PhD, has made the most of the opportunities that have come her way since she...

Social Media

Newsroom

For press inquiries about the Gastric Cancer Foundation, please contact: Mediainfo@gastriccancer.org

Categories

Foundation News
Press Releases
Research News
Your New Normal

Tags

adenocarcenoma advanced stage alcohol antibody biomarker blood chemoradiotherapy chemotherapy clinical trial clinical trials detection drugs endoscopy Epstein-Barr esophagogastric FDA gastrectomy gastric cancer registry gastroesophageal genes heartburn helicobacter pylori HER2 immunotherapy keytruda lonsurf metastatic nutrition peritoneal postoperative prevention proton pump inhibitor recovery recurrence research risk screening side-effects studies surgery survival treatment tumor virus women

Gastric Cancer Foundation

Tax ID 27-2978173

info@gastriccancer.org

PO Box 338
Millbrae, CA 94030

For Deliveries:
Gastric Cancer Foundation
501 Broadway, #338
Millbrae, CA 94030-1907

Site Map

Gastric Cancer
Accelerate Research
Patient Resources
Nutrition
- Eating and Healing
- Gesundheit Kitchen
  - Watch Episodes
  - Printable Recipes
Ways to Give
About Us

Social Feed

Gastric Cancer Foundation

7 days ago

An experimental anti-HER2 bispecific antibody anbenitamab (KN026) from Alphamab Oncology, in combination with chemotherapy, had an objective response rate of 55.8% in patients with HER2-positive gastric cancer, the company announced at the ESMO - European Society for Medical Oncology Congress. The drug, now in phase 2/3 trials in gastric cancer in China, was granted Orphan Drug status by the FDA. #ESMO25 ... See MoreSee Less

www.prnewswire.com

404

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

This #givingtuesday, join us and Commit to a Cure for gastric cancer. Make a donation today. gastriccancer.org/donate ... See MoreSee Less

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 weeks ago

Gilead Sciences and Arcus Biosciences announced positive results from a phase 2 trial of domvanalimab, an anti-TIGIT antibody, combined with immunotherapy and chemotherapy in gastric cancer. A phase 3 trial is now underway. #ESMO25 ... See MoreSee Less

Gilead and Arcus reignite anti-TIGIT interest with Phase II gastric cancer win

www.clinicaltrialsarena.com

Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the past year.

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

3 weeks ago

AstraZeneca announced positive results from a phase 3 clinical trial combining its immunotherapy drug Imfinzi (durvalumab) with chemotherapy in some gastric cancer patients before and after surgery. More than two-thirds of patients were alive at three years, according to data presented at the European Society for Medical Oncology (ESMO) Congress. #ESMO25 ... See MoreSee Less

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

www.astrazeneca.com

Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial PUBLISHED 17 October 2025 More than two thirds of patients treated w...

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Gastric Cancer Foundation

2 months ago

Could AI be the key to improving the early diagnosis of Stomach Cancer? A recent analysis of 19 studies concluded the technology could play a promising role in diagnosis. ... See MoreSee Less

www.sciencedirect.com

www.sciencedirect.com

View on Facebook

· Share

Share on Facebook Share on Twitter Share on Linked In Share by Email

Subscribe to Our Newsletter

We’ll deliver our monthly newsletter to your Inbox with Foundation updates, news about cutting edge research and trends in the field, and how to make a difference.

© 2024 Gastric Cancer Foundation. All Rights Reserved.

EVENTS | NEWS | CONTACT | DONATE

Please join with us to fuel the next wave of progress.

Your support honors the memories of those we have lost and creates much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Please join with us to fuel the next wave of progress. Support our 2025 Fundraising Campaign.

Your support honors the memories of those we have lost and creates much-needed hope for those who are bravely facing the disease today. Contributions are tax-deductible.

Powering progress to defeat stomach cancer.

Powering progress to defeat stomach cancer.

MORE INFO DONATE DONATE MORE INFO

X